CD&D Executive Editor
The publication you have known as Cardiovascular Device Update is now Cardiovascular Devices & Drugs.
This new name reflects an expanded emphasis but the same mission as before — to bring you news of the most up-to-date developments in cardiovascular technologies. The rationale for expanding this emphasis to drugs is multiple.
Every day, this sector produces news concerning the combination of cardiovascular devices and cardiovascular drugs and the critical clinical interplay between the device and pharma sectors. The sentinel event highlighting some of these new combinations was the approval of drug-eluting stents in 2004, and DES technology remains closely linked to the need for a follow-on regimen of antiplatelet therapies.
Additionally, the sector has always been marked by both complementary therapeutic uses of devices and drugs and a competition between them, that competition playing out in clinical studies, the physician’s office and aggresive market battles.
Cardiovascular Devices & Drugs will continue to highlight its original focus on developments in device therapies, but it now will also provide news concerning cardiovascular pharmaceuticals, from early inception to final commercialization, in order to provide a broad look at this important clinical and business landscape.
Cardiovascular technology continues to play out as the No. 1 therapeutic pathway for the development of all types of groundbreaking advances in med-tech. We invite you to continue with us as we travel this exciting path — and its entrepreneurial highways and byways.